GNI Group Ltd. (JP:2160)
:2160
2160 Stock Chart & Stats
¥2290.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥2290.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥1,469.00 - ¥4,410.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)969.16K
Market Cap
¥181.02B
Enterprise Value¥164.95B
Total Cash (Recent Filing)¥21.10B
Total Debt (Recent Filing)¥5.37B
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-74.44
Shares Outstanding55,698,696
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.28
Revenue Forecast (FY)¥41.97B
Bulls Say, Bears Say
Bulls Say
Conservative LeverageA low debt-to-equity (~0.13 in 2025) gives the company durable financial flexibility: it lowers insolvency risk, reduces refinancing pressure, and preserves capacity to fund R&D, partnerships or M&A without immediate reliance on dilutive equity or expensive debt.
High Gross MarginsSustained high gross margins point to strong product-level economics and pricing power. That margin buffer supports long-term investment in R&D and commercialization even if operating expenses rise, improving the prospects for durable profitability once operating leverage recovers.
Long-run Revenue GrowthConsistent multi-year revenue expansion, including a 2025 rebound, indicates durable market demand and product traction. Steady top-line growth supports scaling economics, validates the commercial model, and makes future pipeline monetization and licensing more achievable.
Bears Say
Two-year Cash BurnConsecutive years of negative operating and free cash flow create structural funding risk. The company may need external financing, increasing dilution or leverage, which can constrain strategic execution, slow pipeline development, and pressure long-term returns if cash generation doesn't recover.
2025 Profitability CollapseA sharp swing to meaningful losses in 2025 signals weakening earnings quality and potential structural cost or revenue issues. Persistent losses reduce internal reinvestment capacity, may force cost cuts or restructuring, and raise execution risk for commercial and R&D programs.
Earnings VolatilityExtreme EPS volatility (≈-486% growth) undermines forecasting and capital allocation. Large swings suggest material one-offs or unstable operating performance, which can increase borrowing costs, deter long-term partners, and complicate investor and management planning for multi-year initiatives.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥1469.00 and its highest was ¥4410.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥181.02B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is May 18, 2026 which is in 50 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -¥74.44 earnings per share for the quarter, missing the consensus estimate of ¥224.642 by -¥299.082.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Overvalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,698,696 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -¥74.44 in its last earnings report, missing expectations of ¥224.642. Following the earnings report the stock price went down -3.49%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Peptidream
―
SanBio Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---